查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465571

卵巢癌診斷市場- 依產品類型（儀器/分析儀、消耗品）、診斷測試（影像[CT、MRI、超音波]、血液檢查、活體組織切片）、癌症類型（上皮細胞、生殖細胞、基質細胞腫瘤）、最終用途- 2024 - 2032 年全球預測

Ovarian Cancer Diagnostic Market - By Product Type (Instruments/Analyzers, Consumables), Diagnostic Tests (Imaging [CT, MRI, Ultrasound], Blood Test, Biopsy), Cancer Type (Epithelial, Germ Cell, Stromal Cell Tumor), End-use - Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 250 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在該領域不斷增加的研發力道的推動下，2024 年至 2032 年間，全球卵巢癌診斷市場規模的複合年成長率將達到 6.6%。由於卵巢癌在早期階段很難被發現，因此迫切需要改進的診斷工具和技術。例如，2024 年 1 月，佐治亞理工學院綜合癌症研究中心 (ICRC) 的研究人員將機器學習技術與血液代謝物資料相結合，創建了一種新型測試，能夠在研究隊列的樣本中以93% 的準確率識別卵巢癌。

隨著研究人員深入了解與卵巢癌相關的分子機制和生物標記，創新的診斷方法正在出現。這些進步包括液體活體組織切片技術、基因組分析和影像方式，提供更準確和及時的疾病檢測。因此，醫療保健提供者和患者擴大轉向這些尖端的診斷解決方案，推動了市場需求，並為改善卵巢癌診斷和治療結果帶來了希望。

整個卵巢癌診斷產業根據產品類型、癌症類型、診斷測試、最終用途和地區進行分類。

從 2024 年到 2032 年，消耗品領域將實現顯著的複合年成長率。隨著醫療保健提供者優先考慮早期檢測和個人化治療方法，卵巢癌診斷對高品質耗材的需求持續成長。此外，技術升級和創新耗材產品的推出進一步刺激了市場需求，確保醫療保健專業人員能夠獲得可靠的工具來有效診斷和管理卵巢癌。

從 2024 年到 2032 年，血液檢測領域的卵巢癌診斷市場佔有率將顯著成長。 這些檢測分析血液中與卵巢癌相關的特定生物標記或遺傳特徵，提供方便、高效的診斷解決方案。隨著醫療保健提供者強調早期檢測和個人化治療策略，對血液診斷測試的需求持續成長。此外，血液檢測技術的持續研究和進步進一步推動市場成長，確保透過及時檢測和介入來改善患者的治療結果。

到 2032 年，亞太地區癌症卵巢癌診斷市場將佔據可觀的市場佔有率。醫療保健系統正在優先考慮篩檢計劃和先進診斷技術的使用，以改善患者的治療結果。因此，對卵巢癌診斷測試（包括影像技術和生物標記檢測）的需求持續上升，推動市場成長並促進整個地區醫療保健服務的進步。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 卵巢癌的發生率和盛行率不斷上升
      • 提高認知和篩檢計劃
      • 增加研究和開發活動
      • 卵巢癌診斷的技術進步
    • 產業陷阱與挑戰
      • 治療費用高
      • 嚴格的監管場景
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章：市場估計與預測：按產品類型，2018 年 - 2032 年

  • 主要趨勢
  • 儀器/分析儀
  • 耗材

第 6 章：市場估計與預測：透過診斷測試，2018 - 2032

  • 主要趨勢
  • 影像學檢查
    • 超音波
    • CT掃描
    • 核磁共振掃描
    • 正子斷層掃描
    • 其他影像學檢查
  • 驗血
    • CA125（癌症抗原 125）
    • HER2（人類表皮生長因子受體2）
    • BRCA（乳癌基因）
    • CEA（癌胚抗原）
    • ER & PR（雌激素受體與黃體素受體）
    • KRAS突變
    • 其他血液檢查
  • 活體組織切片
  • 其他診斷測試

第 7 章：市場估計與預測：按癌症類型，2018 年 - 2032 年

  • 主要趨勢
  • 上皮性腫瘤
  • 生殖細胞腫瘤
  • 間質細胞瘤
  • 其他癌症類型

第 8 章：市場估計與預測：按最終用途，2018 - 2032 年

  • 主要趨勢
  • 醫院
  • 診斷實驗室
  • 診斷影像中心
  • 癌症研究機構
  • 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies
  • Canon Medical Systems Corporation
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio Diagnostics
  • GE HealthCare Technologies Inc.
  • Illumina Inc.
  • Myriad Genetics
  • Philips Healthcare
  • Positron Corporation
  • Qiagen N.V.
  • Quest Diagnostics
  • Siemens Healthineers AG
簡介目錄
Product Code: 8316

Global Ovarian Cancer Diagnostic Market size will witness a 6.6% CAGR between 2024 and 2032, driven by increasing research and development efforts in the field. With ovarian cancer being notoriously difficult to detect in its early stages, there is a pressing need for improved diagnostic tools and techniques. For instance, in January 2024, researchers at the Georgia Tech Integrated Cancer Research Center (ICRC) integrated machine learning techniques with data on blood metabolites to create a novel test capable of identifying ovarian cancer with 93% accuracy in samples from their study cohort.

As researchers delve deeper into understanding the molecular mechanisms and biomarkers associated with ovarian cancer, innovative diagnostic methods are emerging. These advancements include liquid biopsy techniques, genomic profiling, and imaging modalities, offering more accurate and timely disease detection. As a result, healthcare providers and patients alike are increasingly turning to these cutting-edge diagnostic solutions, driving market demand and fostering hope for improved outcomes in ovarian cancer diagnosis and treatment.

The overall Ovarian Cancer Diagnostic Industry is classified based on the product type, cancer type, diagnostic tests, end-use, and region.

The consumables segment will register a significant CAGR from 2024 to 2032. These essential components, such as test kits, reagents, and disposable instruments, are crucial for conducting diagnostic procedures accurately and efficiently. As healthcare providers prioritize early detection and personalized treatment approaches, the demand for high-quality consumables in ovarian cancer diagnostics continues to grow. Moreover, technological upgrades and the introduction of innovative consumable products further fuel market demand, ensuring that healthcare professionals have access to reliable tools for effective diagnosis and management of ovarian cancer.

The ovarian cancer diagnostic market share from blood test segment will record noteworthy gains from 2024 to 2032. These tests analyze specific biomarkers or genetic signatures in the blood associated with ovarian cancer, offering a convenient and efficient diagnostic solution. As healthcare providers emphasize early detection and personalized treatment strategies, the demand for blood-based diagnostic tests continues to rise. Moreover, ongoing research and advancements in blood test technologies further drive market growth, ensuring improved outcomes for patients through timely detection and intervention.

Asia Pacific cancer ovarian cancer diagnostic market will register a commendable market share through 2032. With a rising prevalence of ovarian cancer and increasing awareness about early detection, there is a growing demand for reliable diagnostic tools in countries across the Asia Pacific. Healthcare systems are prioritizing screening programs and access to advanced diagnostic technologies to improve patient outcomes. As a result, the demand for ovarian cancer diagnostic tests, including imaging techniques and biomarker assays, continues to escalate, driving market growth and fostering advancements in healthcare delivery throughout the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data sources
    • 1.5.1 Primary
    • 1.5.2 Secondary
      • 1.5.2.1 Paid sources
      • 1.5.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence and prevalence of ovarian cancer
      • 3.2.1.2 Growing awareness and screening programs
      • 3.2.1.3 Increasing research and development activities
      • 3.2.1.4 Technological advancements in ovarian cancer diagnostics
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High treatment costs
      • 3.2.2.2 Stringent regulatory scenario
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments/analyzers
  • 5.3 Consumables

Chapter 6 Market Estimates and Forecast, By Diagnostic Tests, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Imaging test
    • 6.2.1 Ultrasound
    • 6.2.2 CT scan
    • 6.2.3 MRI scan
    • 6.2.4 PET scan
    • 6.2.5 Other imaging tests
  • 6.3 Blood test
    • 6.3.1 CA125 (Cancer antigen 125)
    • 6.3.2 HER2 (Human epidermal growth factor receptor 2)
    • 6.3.3 BRCA (Breast cancer gene)
    • 6.3.4 CEA (Carcinoembryonic antigen)
    • 6.3.5 ER & PR (Estrogen receptor and progesterone receptor)
    • 6.3.6 KRAS mutation
    • 6.3.7 Other blood tests
  • 6.4 Biopsy
  • 6.5 Other diagnostic tests

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Epithelial tumor
  • 7.3 Germ cell tumor
  • 7.4 Stromal cell tumor
  • 7.5 Other cancer types

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Diagnostic laboratories
  • 8.4 Diagnostic imaging centers
  • 8.5 Cancer research institutes
  • 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Agilent Technologies
  • 10.3 Canon Medical Systems Corporation
  • 10.4 Danaher Corporation
  • 10.5 F. Hoffmann-La Roche Ltd.
  • 10.6 Fujirebio Diagnostics
  • 10.7 GE HealthCare Technologies Inc.
  • 10.8 Illumina Inc.
  • 10.9 Myriad Genetics
  • 10.10 Philips Healthcare
  • 10.11 Positron Corporation
  • 10.12 Qiagen N.V.
  • 10.13 Quest Diagnostics
  • 10.14 Siemens Healthineers AG